Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Trim from Needham & Company LLC

01 Nov 2026, 05:42 by Kim Johansen · The Markets Daily

Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price reduced by Needham & Company LLC from $357.00 to $243.00 in a report released on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. Zacks Research lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, October 23rd. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Barclays decreased their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. Finally, Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $317.95.

Get Our Latest Research Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Trading Down 5.2%

NASDAQ:ALNY opened at $165.00 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The firm has a 50-day moving average of $236.49 and a 200-day moving average of $286.19. The company has a market cap of $22.08 billion, a PE ratio of 8.57 and a beta of 0.28. Alnylam Pharmaceuticals has a one year low of $163.30 and a one year high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 246.94%. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the business posted $2.90 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year. As a group, equities research analysts expect that Alnylam Pharmaceuticals will post 6.58 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $34,784,000. WINTON GROUP Ltd bought a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $2,372,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $50,773,000. Silvant Capital Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $5,456,000. Finally, Wealthfront Advisers LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $2,876,000. Institutional investors own 92.97% of the company’s stock.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.